GlassScriptPhysician profile
Nandini Ignatius
NPI 1235462128
$11,836.78
in general payments reported to CMS, 2019-2025
81 companies · $2,616 in 2025
The $2,616 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $1,140 · 2021: $1,560 · 2022: $2,525 · 2023: $1,937 · 2024: $954 · 2025: $2,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479 · Consulting Fee: $2,010 · Education: $17.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.10 |
| Consulting Fee | $2,010.00 |
| Education | $17.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,246.36 | 2020-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $965.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $848.90 | 2019-2024 | Opdualag, Opdivo |
| Janssen Biotech, INC. | $464.20 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Genzyme Corporation | $424.26 | 2019-2025 | |
| Celgene Corporation | $396.80 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $382.15 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $368.96 | 2019-2025 | |
| Seagen INC. | $327.01 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $320.11 | 2020-2025 | Jakafi |
| Pfizer INC. | $309.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.24 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $300.45 | 2019-2025 | Enhertu, Calquence |
| Amgen INC. | $299.81 | 2020-2023 | Kyprolis |
| Astellas Pharma US INC | $254.92 | 2019-2025 | Padcev, Xtandi |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $211.07 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Kite Pharma, INC. | $193.77 | 2021-2023 | |
| Abbvie INC. | $192.68 | 2019-2025 | |
| Puma Biotechnology, INC. | $182.15 | 2020-2025 | |
| Stemline Therapeutics INC. | $162.56 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $133.26 | 2019-2025 | Alunbrig |
| Emd Serono, INC. | $130.96 | 2020-2021 | |
| Gilead Sciences, INC. | $119.84 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $118.46 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Array Biopharma INC | $107.72 | 2020-2024 | Mektovi, Braftovi, Tukysa |
| Genentech USA, INC. | $107.18 | 2019-2024 | Lunsumio, Venclexta, Columvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.17 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $76.55 | 2022-2025 | Monoferric, Cosela |
| Kyowa Kirin, INC. | $75.09 | 2020-2023 | Poteligeo |
| Taiho Oncology, INC. | $71.66 | 2019-2024 | |
| Coherus Oncology, INC. | $70.88 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $59.83 | 2023-2024 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $59.68 | 2023-2024 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $58.51 | 2019-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $56.92 | 2020-2021 | |
| Ge Healthcare | $55.54 | 2021 | |
| Servier Pharmaceuticals LLC | $53.86 | 2023-2025 | |
| G1 Therapeutics, INC. | $52.01 | 2022-2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $51.46 | 2022-2023 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $48.69 | 2023 | Epkinly |
| Exelixis INC. | $48.55 | 2019-2025 | Cabometyx |
| Mirati Therapeutics, INC. | $48.28 | 2023-2024 | Krazati |
| Sobi, INC | $47.48 | 2023-2024 | |
| Myovant Sciences INC. | $46.28 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $45.57 | 2019-2023 | Onivyde, Somatuline Depot |
| Epizyme, INC. | $44.44 | 2021-2023 | Tazverik |
| Blueprint Medicines Corporation | $42.55 | 2020-2024 | Ayvakit |
| Myriad Genetic Laboratories, INC. | $37.87 | 2025 | Myrisk |
| Springworks Therapeutics, INC. | $37.82 | 2024 | Ogsiveo |
| Beigene USA, INC. | $37.58 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $34.38 | 2024-2025 | Vivimusta, Danziten |
| Apellis Pharmaceuticals, INC. | $34.21 | 2022-2024 | Empaveli |
| Pharmaessentia USA Corporation | $33.14 | 2023-2025 | Besremi |
| Octapharma USA, INC. | $32.33 | 2020-2024 | Panzyga |
| Karyopharm Therapeutics INC. | $31.70 | 2022-2023 | Xpovio |
| Foundation Medicine, INC. | $29.58 | 2020 | |
| Dendreon Pharmaceuticals LLC | $29.29 | 2024 | Provenge |
| Morphosys, US INC. | $29.13 | 2022 | |
| Acceleron Pharma, INC. | $27.96 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.69 | 2021-2023 | Libtayo |
| Mylan Institutional INC. | $27.02 | 2019-2022 | |
| Novocure INC. | $26.01 | 2025 | Optune Lua (Novottf-200t) |
| Spectrum Pharmaceuticals INC. | $23.10 | 2023 | Rolvedon |
| Janssen Pharmaceuticals, INC | $22.56 | 2024 | Xarelto |
| Agios Pharmaceuticals, INC. | $19.57 | 2023 | Pyrukynd |
| Tempus Ai, INC | $18.66 | 2025 | Xt Cdx |
| Aadi Bioscience, INC. | $17.38 | 2023 | Fyarro |
| Alexion Pharmaceuticals, INC. | $16.58 | 2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $16.07 | 2025 | Orgovyx |
| Teva Pharmaceuticals USA, INC. | $15.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2020 | |
| Tesaro, INC. | $14.97 | 2019 | |
| Horizon Therapeutics Plc | $14.68 | 2022 | |
| Immunogen, INC. | $14.56 | 2023 | Elahere |
| Sirtex Medical INC | $14.40 | 2019 | |
| Global Blood Therapeutics, INC. | $13.70 | 2021 | |
| Eusa Pharma (US) LLC | $13.64 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.52 | 2020 | |
| Clovis Oncology, INC. | $13.37 | 2019 | |
| Adc Therapeutics America, INC. | $11.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nandini Ignatius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.